Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Faron Pharmaceuticals Oy's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 105.92%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Faron Pharmaceuticals Oy's 3-Year ROIIC % or its related term are showing as below:
FRA:4FR's 3-Year ROIIC % is ranked better than 78.84% of 1323
companies
in the Biotechnology industry
Industry Median: -4.85
vs FRA:4FR: 105.92
Faron Pharmaceuticals Oy (FRA:4FR) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Faron Pharmaceuticals Oy 3-Year ROIIC % Related Terms
Faron Pharmaceuticals Oy 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4FR vs VRTX, REGN, ALNY: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Faron Pharmaceuticals Oy's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faron Pharmaceuticals Oy 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Faron Pharmaceuticals Oy's 3-Year ROIIC % falls into.
Faron Pharmaceuticals Oy 3-Year ROIIC % Calculation
Faron Pharmaceuticals Oy's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -18.959 (Dec. 2025) - -27.426 (Dec. 2022) )
/
( 14.676 (Dec. 2025) - 6.87 (Dec. 2022) )
=
8.467
/
7.806
=
108.47%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Faron Pharmaceuticals Oy (FRA:4FR) has a 3-Year ROIIC % of 105.92 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Faron Pharmaceuticals Oy and its competitors. According to the industry distribution chart, Faron Pharmaceuticals Oy ranks #280 out of 1323 companies in the Biotechnology industry, placing it in the top 21.2%.
Is Faron Pharmaceuticals Oy's 3-Year ROIIC % too high?
Faron Pharmaceuticals Oy's current 3-Year ROIIC % is 105.92. Based on the distribution chart, Faron Pharmaceuticals Oy ranks #280 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Faron Pharmaceuticals Oy ranks #280 out of 1323 companies for 3-Year ROIIC %. This places Faron Pharmaceuticals Oy in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Faron Pharmaceuticals Oy and its competitors. Faron Pharmaceuticals Oy's current 3-Year ROIIC % is 105.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current 3-Year ROIIC % of 105.92. The current 3-Year ROIIC % is 105.92. Faron Pharmaceuticals Oy's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current 3-Year ROIIC % is 105.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
28GF Score
Get the complete analysis for FRA:4FR
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4FR has been successfully added to your 
